Harvinder Arora, MD
Interventional Cardiology · Tavares, FLNPI 1891922134
Payments from drug & device makers
Across 339 payments — averaging $67.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Medtronic$5K
- Abiomed$1K
- Boston Scientific$1K
- Medical Device Business Services, Inc.$986
- Inari Medical, Inc.$898
- plus $4K from 28 others
What the payments were for
- Travel & lodging$11,52951%
- Food & beverage$11,08649%
- Education$2111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 78 | $9,078 |
| Medtronic(2 entities) | 47 | $5,260 |
| Abiomed | 26 | $1,287 |
| Boston Scientific | 23 | $1,121 |
| Medical Device Business Services, Inc. | 4 | $986 |
| Inari Medical, Inc. | 2 | $898 |
| Baylis Medical Company Inc | 6 | $861 |
| AstraZeneca | 29 | $613 |
| Edwards Lifesciences | 13 | $428 |
| Novartis | 41 | $356 |
| Johnson & Johnson | 23 | $344 |
| Terumo Medical Corporation | 3 | $241 |
| Penumbra, Inc. | 5 | $210 |
| Shockwave Medical, Inc | 2 | $162 |
| Heartflow, Inc. | 1 | $139 |
| Cardiovascular Systems Inc. | 6 | $119 |
| Intuitive Surgical | 1 | $117 |
| Biosense Webster, Inc. | 3 | $102 |
| Angiodynamics, Inc. | 1 | $94 |
| Amgen | 6 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Merck | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Merit Medical Systems Inc | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Cvrx, Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| EKOS Corporation | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$1,629
- COREVALVE EVOLUT R$1,619
- AVEIR$1,311
- Micra$1,190
- Perclose ProStyle$1,078
- MitraClip$1,010
- Carto 3$986
- Diamondback Peripheral$943
- VenaSeal$885
- VersaCross Access Solution$711
- GENERAL VASCULAR ACCESS$571
- Impella$270
- JETi Peripheral Catheter$270
- AMPLATZER AMULET$252
- Supera peripheral stent system$249
- OPTIS$238
- GLIDESHEATH SLENDER$214
- XIENCE SIERRA$181
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- Perclose ProGlide suture mediated closure system$137
How this compares
$22,826 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $123,859 |
| XareltoRivaroxaban | 63 | $55,285 |
| FarxigaDapagliflozin Propanediol | 44 | $44,135 |
| EntrestoSacubitril/Valsartan | 20 | $16,239 |
| JardianceEmpagliflozin | 11 | $14,483 |
| BrilintaTicagrelor | 20 | $11,687 |
| NexletolBempedoic Acid | 12 | $6,328 |
| Ranolazine ErRanolazine | 36 | $3,794 |
| ClopidogrelClopidogrel Bisulfate | 218 | $2,602 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $2,258 |
| Metoprolol Succinate | 127 | $1,606 |
| Clonidine | 21 | $1,346 |
| Cilostazol | 59 | $1,270 |
| Midodrine Hcl | 13 | $1,208 |
| Atorvastatin Calcium | 140 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $123,859155 claims |
| AstraZenecaFarxiga, Brilinta | $613 | $55,82364 claims |
| Johnson & JohnsonXarelto | $344 | $55,28563 claims |
| NovartisEntresto | $356 | $16,23920 claims |
| Boehringer IngelheimJardiance | $26 | $14,48311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Tavares
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.